Investigate the differences between treating Chronic Kidney Disease - Mineral and Bone Disorder with an iron-containing phosphate binder or a calcium-containing phosphate binder in Chronic Kidney Disease stage 3-5.
Latest Information Update: 20 Jan 2020
At a glance
- Drugs Sucroferric oxyhydroxide (Primary) ; Sodium fluoride
- Indications Bone disorders; Hyperphosphataemia; Mineral metabolism disorders
- Focus Pharmacodynamics
- Acronyms MIVI
- 17 Jan 2020 Status changed from recruiting to discontinued.
- 05 Oct 2017 New trial record